Do Statins have a Role in Reduction/Prevention of Post-PCI Restenosis?

Cardiovascular Therapeutics

Volumn 31, Issue 1, 2013, Pages 12-26

  Prasad, Kailash ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Myonecrosis; Pathophysiology of neointimal formation; Pleiotropic effects of statins; Post PCI restenosis; Reduction of restenosis; Repeat revascularization; Risk factors for restenosis; Statins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ATORVASTATIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CERIVASTATIN; CERULOPLASMIN; CLOPIDOGREL; CYCLOOXYGENASE 2; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; NITRIC OXIDE; OXYGEN RADICAL; PRAVASTATIN; SIMVASTATIN; UBIDECARENONE;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG ELUTING STENT; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; ENDOTHELIUM CELL; EVENING DOSAGE; EXTRACELLULAR MATRIX; HEART MUSCLE INJURY; HUMAN; HYPERLIPIDEMIA; IN-STENT RESTENOSIS; LOADING DRUG DOSE; LOW DRUG DOSE; MUSCLE NECROSIS; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RESTENOSIS; REVIEW; SINGLE DRUG DOSE; SMOOTH MUSCLE FIBER; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VASCULAR SMOOTH MUSCLE;

CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; CORONARY VESSELS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; NEOINTIMA; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; STENTS; TREATMENT OUTCOME;

EID: 84872308121     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00302.x     Document Type: Review

References (278)

1. Gruntzig AR. Transluminal dilatation of coronary artery stenosis [letter]. Lancet 1978;1:263.
2. Bauters C, Isner JM. The biology of restenosis. In: Topol EJ, editor. Textbook of cardiovascular medicine. Philadelphia: Lippincott-Raven, 1998;2465-2490.
3. Macaya C, Serruys PW, Ruygrok P, et al.Benestent Study group. Continued benefit of coronary stenting versus balloon angioplasty: One-year clinical follow up of Benestent trial. J Am Coll Cardiol 1996;27:255-264.
4. Stone GW, Ellis SG, Cox DA, et al.TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Eng J Med 2004;350:221-231.
5. Lemos PA, Saia F, Ligthart JM, et al.Coronary restenosis after sirolimus-eluting stent implantation: Morphological description and mechanistic analysis from a consecutive series of cases. Circulation 2003;108:257-260.
6. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992;13:134-136.
7. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335-340.
8. Morice MC, Serruys PW, Sousa JE, et al.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
9. Grube E, Silber S, Hauptmann KE, et al.TAXUS I: Six- and twelve-month results forma randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
10. Hong SJ, Kim MH, Ahn TH, et al.Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. Heart 2006;92:1119-1124.
11. Nikol S, Huehns TY, Hofling B. Molecular biology and post-angioplasty restenosis. Atherosclerosis 1996;123:17-31.
12. Rajagopal V, Rockson SG. Coronary restenosis: A review of mechanisms and management. Am J Med 2003;115:547-553.
13. Saleh N, Tornvall P. Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis. Atherosclerosis 2007;195:374-378.
14. Tashiro H, Shimokawa H, Sadamatsu K, Aoki T, Yamamoto K. Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty. Coron Artery Dis 2001;12:107-113.
15. Inoue T, Uchida T, Yaguchi I, Sakai Y, Takayanagi K, Morooka S. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation 2003;107:1757-1763.
16. Schmidt AM, Yan S, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489-497.
17. Sakaguchi T, Yan SF, Yan SD, et al.Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003;111:959-972.
18. Moreno PR, Palacios IF, Leon MN, Rhodes J, Fuster V, Fallon JT. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am J Cardiol 1999;84:462-466.
19. Weintraub WS. The pathophysiology and burden of restenosis. Am J Cardiol 2007;100:3K-9K.
20. Caixeta AM, Arie S, Sândoli de Brito F Jr., et al. Analysis of elastic retraction in the 1st 15 minutes after coronary balloon angioplasty [in Portuguese]. Arq Bras Cardiol 1996;66:5-9.
21. Rozenman Y, Gilon D, Welber S, Sapoznikov D, Gotsman MS. Clinical and angiographic predictors of immediate recoil after successful coronary angioplasty and relation to late restenosis. Am J Cardiol 1993;72:1020-1025.
22. Schwartz RS. Pathophysiology of restenosis: Interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol 1998;81:14E-17E.
23. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: Current status and future strategies. J Am Coll Cardiol 2002;39:183-193.
24. Casscells W, Engler D, Willerson JT. Mechanisms of restenosis. Tex Heart Inst J 1994;21:68-77.
25. Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. Rev Cardiovasc Med 2002;3(Suppl 5):S4-S9.
26. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Müller KM. Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen. J Am Coll Cardiol 2000;35:157-163.
27. Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997;96:2280-2286.
28. Riessen R, Wight TN, Pastore C, Henley C, Isner JM. Distribution of hyaluronan during extracellular matrix remodeling in human restenotic arteries and balloon-injured rat carotid arteries. Circulation 1996;93:1141-1147.
29. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010;56:1897-1907.
30. Zahn R, Hamm CW, Schneider S, et al.Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicentre German Cypher Stent Registry). Am J Cardiol 2005;95:1302-1308.
31. Kastrati A, Dibra A, Mehilli J, et al.Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006;113:2293-2300.
32. Monraats PS, Pires NM, Agema WR, et al.Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 2005;112:2417-2425.
33. Kastrati A, Dirschinger J, Schömig A. Genetic risk factors and restenosis after percutaneous coronary interventions. Herz 2000;25:34-46.
34. Mackiewicz A, Speroff T, Ganapathi MK, Kushner I. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 1991;146:3032-3037.
35. Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl 2003;134:10-17.
36. Buffon A, Liuzzo G, Biasucci LM, et al.Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-1521.
37. Ishikawa T, Hatakeyama K, Imamura T, et al.Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol 2003;91:287-292.
38. de Winter RJ, Koch KT, van Straalen JP, et al.C-reactive protein and coronary events following percutaneous coronary angioplasty. Am J Med 2003;115:85-90.
39. Zairis MN, Ambrose JA, Manousakis SJ, et al.The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 2002;40:1375-1382.
40. Rittersma SZ, de Winter RJ, Koch KT, et al.Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement. Clin Chem 2004;50:1589-1596.
41. Kumar A, Cannon CP. Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention. J Interv Cardiol 2007;20:447-457.
42. Hoshida S, Nishino M, Takeda T, Tanouchi J, Yamada Y, Hori M. A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins. Atherosclerosis 2004;173:285-290.
43. Dibra A, Mehilli J, Braun S, et al.Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J 2005;150:344-350.
44. Gaspardone A, Crea F, Varsaci F, et al.Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998;82:515-518.
45. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schäginger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001;37:839-846.
46. Azar RR, McKay RG, Kiernan FJ, et al.Coronary angioplasty induces a systemic inflammatory response. Am J Cardiol 1997;80:1476-1478.
47. Angioi M, Abdelmouttaleb I, Rodriguez RM, et al.Increased C-reactive protein levels in patients with in-stent restenosis and its implications. Am J Cardiol 2001;87:1189-1193.
48. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, et al.Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000;21:1152-1158.
49. Cirillo P, Golino P, Calabrò P, et al.C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 2005;68:47-55.
50. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-520.
51. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. Circulation 2003;107:398-404.
52. Potempa LA, Zeller JM, Fiedel BA, Kinoshita CM, Gewurz H. Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. Inflammation 1988;12:391-405.
53. Prasad K. C-reactive protein and cardiovascular diseases. Int J Angiol 2003;12:1-12.
54. Bennermo M, Held C, Ericsson CG, Silveira A, Hamsten A, Tornvall P. Genotype-specific increase in plasma concentrations of activated coagulation factor VII in response to experimental inflammation. A link between infection and acute myocardial infarction?Thromb Haemost 2005;94:427-431.
55. Verma S, Wang CH, Li SH, et al.A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-919.
56. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001;88:756-762.
57. Harbrecht BG, Billiar TR, Stadler J, et al.Inhibition of nitric oxide synthesis during endotoxemia promotes intrahepatic thrombosis and an oxygen radical-mediated hepatic injury. J Leukoc Biol 1992;52:390-394.
58. Wang CH, Li SH, Weisel RD, et al.C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003;107:1783-1790.
59. Ho KJ, Owens CD, Longo T, Sui XX, Ifantides C, Conte MS. C-reactive protein and vein graft disease: Evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor-beta. Am J Physiol Heart Circ Physiol 2008;295:H1132-H1140.
60. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 2003;58:186-195.
61. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003;108:1930-1932.
62. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001;158:1039-1051.
63. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
64. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-2534.
65. Torzewski M, Rist C, Mortensen RF, et al.C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-2099.
66. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultures human monocytes by C-reactive protein. Cytokine 1992;4:361-368.
67. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: Risk marker or mediator in atherothrombosis?Hypertension 2004;44:6-11.
68. Verma S, Li SH, Badiwala MV, et al.Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-1896.
69. Devaraj S, Yun JM, Duncan-Staley C, Jialal I. C-reactive protein induces M-CSF release and macrophage proliferation. J Leukoc Biol 2009;85:262-267.
70. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
71. Young JL, Libby P, Schönbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002;88:554-567.
72. Blankenberg S, Barbaux S, Tieret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003;170:191-203.
73. Verma S, Yeh ET. C-reactive protein and atherothrombosis-beyond a biomarker: An actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol 2003;285:R1253-R1256.
74. Prasad K. C-reactive protein increases oxygen radical generation by neutrophils. J Cardiovasc Pharmacol Ther 2004;9:203-209.
75. Kobayashi S, Inoue N, Ohashi Y, et al.Interaction of oxidative stress and inflammatory response in coronary plaque instability: Important role of C-reactive protein. Arterioscler Thromb Vasc Biol 2003;23:1398-1404.
76. Venugopal SK, Devaraj S, Jialal I. C-reactive protein decreases prostcyclin release from human aortic endothelial cells. Circulation 2003;108:1676-1678.
77. Devaraj S, Dasu MR, Singh U, Rao LV, Jialal I. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis 2009;203:67-74.
78. Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 1999;99:1355-1362.
79. Prasad K, Kalra J, Lee P. Oxygen radicals as a mechanism of hypercholesterolemic atherosclerosis. Int J Angiol 1994;3:100-112.
80. Steinberg D. Antioxidants in the prevention of human atherosclerosis. Circulation 1992;85:2337-2344.
81. Prasad K. Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed. Atherosclerosis 2005;179:269-275.
82. Inoue T, Kato T, Hikichi Y, et al.Stent-induced neutrophil activation is associated with an oxidative burst in the inflammatory process, leading to neointimal thickening. Thromb Haemost 2006;95:43-48.
83. Roberts MJ, Young IS, Trouton TG, et al.Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet 1990;336:143-145.
84. De Scheerder IK, van de Kraay AM, Lamers JM, Koster JF, de Jong JW, Serruys PW. Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: Potential mechanisms for free radical generation. Am J Cardiol 1991;68:392-395.
85. Rajkumar ARJ, Prasad K, Mantha SV, Khouri M, Raney B. Protection of coronary angioplasty-induced oxidative stress by Isovue used during angioplasty. Can J Cardiol 1999;15:989-998.
86. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002;22:1769-1776.
87. Neumann FJ, Ott I, Gawaz M, Puchner G, Schömig A. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol 1996;27:819-824.
88. Inoue T, Sohma R, Miyazaki T, Iwasaki Y, Yaguchi I, Morooka S. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol 2000;86:1057-1062.
89. Welt FG, Edelman ER, Simon DI, Rogers C. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler Thromb Vasc Biol 2000;20:2553-2558.
90. Tardif JC, Grégoire J, L'Allier PL. Prevention of restenosis with antioxidants: Mechanisms and implications. Am J Cardiovasc Drugs 2002;2:323-334.
91. Polack B, Pernod G, Barro C, Doussière J. Role of oxygen radicals in tissue factor induction by endotoxin in blood monocytes. Haemostasis 1997;27:193-200.
92. Golino P, Ragni M, Cirillo P, et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med 1996;2:35-40.
93. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 2000;22:401-404.
94. Chiu JJ, Wung BS, Shyy JY, Hsieh HJ, Wang DL. Reactive oxygen species are involved in shear stress-induced intercellular adhesion molecule-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 1997;17:3570-3577.
95. Keck T, Werner J, Banafsche R, et al. Oxygen radicals promote ICAM-1 expression and microcirculatory disturbances in experimental acute pancreatitis. Pancreatology 2001;3:156-163.
96. Marui N, Offermann MK, Swerlick R, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993;92:1866-1874.
97. Lyle AN, Griendling KK. Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology 2006;21:269-280.
98. Cakir Y, Ballinger SW. Reactive species-mediated regulation of cell signaling and the cell cycle: The role of MAPK. Antiox Redox Signal 2005;7:726-740.
99. Rothstein EC, Lucchesi PA. Redox control of the cell cycle: A radical encounter. Antiox Redox Signal 2005;7:701-703.
100. Irani K. Oxidant signaling in vascular cell growth, death, and survival: A review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000;87:179-183.
101. Sarkar R, Gordon D, Stanley JC, Webb RC. Cell cycle effects of nitric oxide on vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 1997;272:H1810-H1818.
102. Weber DS, Rocic P, Mellis AM, et al. Angiotensin II-induced hypertrophy is potentiated in mice overexpressing p22phox in vascular smooth muscle. Am J Physiol Heart Circ Physiol 2005;288:H37-H42.
103. Nishio E, Watanabe Y. The involvement of reactive oxygen species and arachidonic acid in alpha 1-adrenoreceptor-induced smooth muscle cell proliferation and migration. Br J Pharmacol 1997;121:665-670.
104. Velarde V, de la Cerda PM, Duarte C, et al. Role of reactive oxygen species in bradykinin-induced proliferation of vascular smooth muscle cells. Biol Res 2004;37:419-430.
105. Watson PA, Nesterova A, Burant CF, Klemm DJ, Reusch JE. Diabetes-related changes in cAMP response element-binding protein content enhance smooth muscle cell proliferation and migration. J Biol Chem 2001;276:46142-46150.
106. Abid MR, Kachra Z, Spokes KC, Aird WC. NADPH oxidase activity is required for endothelial cell proliferation and migration. FEBS Lett 2000;486:252-256.
107. Ushio-Fukai M, Tang Y, Fukai T, et al. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res 2002;91:1160-1167.
108. Moldovan L, Mythreye K, Goldschmidt-Clermont PJ, Satterwhite LL. Reactive oxygen species in vascular endothelial cell motility. Roles of NAD(P)H oxidase and Rac1. Cardiovasc Res 2006;71:236-246.
109. Orford JL, Selwyn AP, Ganz P, Popma JJ, Rogers C. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol 2000;86:6H-11H.
110. Schillinger M, Haumer M, Schlerka G, et al. Restenosis after percutaneous transluminal angioplasty in the femoropopliteal segment: The role of inflammation. J Endovasc Ther 2001;8:477-483.
111. Cipollone F, Marini M, Fazia M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 2001;21:327-334.
112. Tashiro H, Shimokawa H, Sadamatsu K, Aoki T, Yamamoto K. Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty. Coron Artery Dis 2001;12:107-113.
113. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002;105:2974-2980.
114. Hokimoto S, Oike Y, Saito T, et al. Increased expression of monocyte chemoattractant protein-1 in atherectomy specimens from patients with restenosis after percutaneous transluminal coronary angioplasty. Circ J 2002;66:114-116.
115. Pietersma A, Kofflard M, de Wit LE, et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation 1995;91:1320-1325.
116. Exner M, Schillinger M, Minar E, et al. Interleukin-6 promoter genotype and restenosis after femoropopliteal balloon angioplasty: Initial observations. Radiology 2004;231:839-844.
117. Funayama H, Ishikawa SE, Kubo N, Yasu T, Saito M, Kawakami M. Close association of regional interleukin-6 levels in the infarct-related culprit coronary artery with restenosis in acute myocardial infarction. Circ J 2006;70:426-429.
118. Qi X, Li S, Li J. The prognostic value of IL-8 for cardiac events and restenosis in patients with coronary heart diseases after percutaneous coronary intervention. Jpn Heart J 2003;44:451-461.
119. McNair ED, Wells CR, Qureshi AM, et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol 2010;33:678-685.
120. Gulesserian T, Wenzel C, Endler G, et al. Clinical restenosis after coronary stent implantation is associated with the heme oxygenase-1 gene promoter polymorphism and the heme oxygenase-1 +99G/C variant. Clin Chem 2005;51:1661-1665.
121. Libby P, Simon DI. Inflammation and thrombosis: The clot thickens. Circulation 2001;103:1718-1720.
122. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989;86:2839-2843.
123. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002;300:729-735.
124. Ernofsson M, Siegbahn A. Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. Thromb Res 1996;83:317-320.
125. Grabowski EF, Lam FP. Endothelial cell function, including tissue factor expression, under flow conditions. Thromb Haemost 1995;74:123-128.
126. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000;85:967-972.
127. Edgington TS, Mackman N, Fan ST, Ruf W. Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouv Rev Fr Hematol 1992;34:S15-S27.
128. Moreno PR, Bernardi VH, López-Cuéllar J, et al. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation 1996;95:3098-3102.
129. Qiao JH, Tripathi J, Mishra NK, et al. Role of macrophage colony-stimulating factor in atherosclerosis: Studies of osteopetrotic mice. Am J Pathol 1997;150:1687-1699.
130. Liu MW, Berk BC. Restenosis following coronary balloon angioplasty. Role of smooth muscle cell proliferation. Trends Cardiovasc Med 1991;1:107-111.
131. Berk BC. Vascular smooth muscle growth: Autocrine growth mechanisms. Physiol Rev 2001;81:999-1030.
132. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006;69:614-624.
133. Goetze S, Xi XP, Kawano Y, et al. TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 1999;33:183-189.
134. Rajesh M, Mukhopadhyay P, Haskó G, Huffman JW, Mackie K, Pacher P. CB2 cannabinoid receptor agonists attenuate the TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 2008;153:347-357.
135. Li A, Varney ML, Valasek J, Godfrey M, Dave BJ, Singh RK. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 2005;8:63-71.
136. Yao JS, Zhai W, Young WL, Yang GY. Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: The role for KDR and MMP-9. Biochem Biophys Res Commun 2006;342:1396-1404.
137. Sugano M, Tsuchida K, Tomita H, Makino N. Increased proliferation of endothelial cells with overexpression of soluble TNF-alpha receptor 1 gene. Atherosclerosis 2002;162:77-84.
138. Cai G, Lian J, Shapiro SS, Beacham DA. Evaluation of endothelial cell migration with a novel in vitro assay system. Methods Cell Sci 2000;22:107-114.
139. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-2476.
140. Bochner BS, Luscinskas FW, Gimbrone MA, et al. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: Contributions of endothelial cell adhesion molecules. J Exp Med 1991;173:1553-1557.
141. Furuzawa-Carballeda J, Alcocer-Varela J. Interleukin-8, interleukin-10, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression levels are higher in synovial tissue from patients with rheumatoid arthritis than in osteoarthritis. Scand J Immunol 1999;50:215-222.
142. McCarty JM, Yee EK, Deisher TA, Harlan JM, Kaushansky K. Interleukin-4 induces endothelial vascular cell adhesion molecule-1 (VCAM-1) by an NF-kappa b-independent mechanism. FEBS Lett 1995;372:194-198.
143. Couffinhal T, Duplàa C, Moreau C, Lamazière JM, Bonnet J. Regulation of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in human vascular smooth muscle cells. Circ Res 1994;74:225-234.
144. Yang WS, Kim BS, Lee SK, Park JS, Kim SB. Interleukin-1beta stimulates the production of extracellular matrix in cultured human peritoneal mesothelial cells. Perit Dial Int 1999;19:211-220.
145. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992;90:1479-1485.
146. Monroe JG, Haldar S, Prystowsky MB, Lammie P. Lymphokine regulation of inflammatory processes: Inteleukin-4 stimulates fibroblast proliferation. Clin Immunol Immunopathol 1988;49:292-298.
147. Postlethwaite AE, Seyer JM. Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70-88 and 89-122. J Clin Invest 1991;87:2147-2152.
148. Bucala R, Cerami A. Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992;23:1-34.
149. Prasad K. Soluble receptors for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol 2006;15:57-68.
150. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000;1498:99-111.
151. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel slice variants of the receptor for advanced glycation end products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-1109.
152. Hudson BI, Harja E, Moser B, Schmidt AM. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: The next C-reactive protein?Arterioscler Thromb Vasc Biol 2005;25:879-882.
153. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889-901.
154. Reznikov LL, Waksman J, Azam T, et al. Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol 2004;61:324-336.
155. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994;12:141-179.
156. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-9897.
157. Prasad K, Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis 2007;192:313-322.
158. Schmidt AM, Stern D. Atherosclerosis and diabetes: The RAGE connection. Curr Atheroscler Rep 2000;2:430-436.
159. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: From disease marker to potential therapeutic target. Curr Med Chem 2006;13:1971-1978.
160. Higashi T, Sano H, Saishoji T, et al. The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes 1997;46:463-472.
161. Bucciarelli LG, Wendt T, Rong L, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: Implications for homeostasis and chronic disease. Cell Mol Life Sci 2002;59:1117-1128.
162. Kislinger T, Tanji N, Wendt T, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001;21:905-110.
163. Wendt T, Bucciarelli LG, Lu Y, et al. Accelerated atherosclerosis and vascular inflammation develop in apoE null mice with type 2 diabetes. Circulation 2000;102:II-231 (Abstract).
164. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 1998;4:1025-1031.
165. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002;106:2827-2835.
166. Zhou Z, Wang K, Penn MS, et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003;107:2238-2243.
167. Falcone C, Emanuele E, D'Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005;25:1032-1037.
168. McNair ED, Wells CR, Qureshi AM, et al. Low levels of soluble receptor for advanced glycation end products in non-ST-elevation myocardial infarction patients. Int J Angiol 2009;18:187-192.
169. Basta G, Berti S, Cocci F, et al. Plasma N-epsilon-(carboxymethyl)lysine levels are associated with the extent of vessel injury after coronary arterial stenting. Coron Artery Dis 2008;19:299-305.
170. Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 2006;70:218-224.
171. An XF, Zhao Y, Yu JY, Liu JS, Gu WJ, Gao F. Plasma sRAGE is independently associated with high sensitivity C-reactive protein in type 2 diabetes without coronary artery disease. Diabetes Res Clin Pract 2010;87:e19-e22.
172. McNair ED, Wells CR, Qureshi AM, et al. Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products. Mol Cell Biochem 2010;341:135-138.
173. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
174. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-1357.
175. Hatzitolios AI, Athyros VG, Karagiannis A, et al. Implementation of strategy for management for overt dyslipidemia: The IMPROVE-dyslipidemia study. Int J Cardiol 2009;134:322-329.
176. Aikawa M, Voglic SJ, Sugiyama S, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999;100:1215-1222.
177. Aikawa M, Sugiyama S, Hill CC, et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 2002;106:1390-1396.
178. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-1082.
179. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: New concepts for cardiovascular disease. Cardiovasc Res 2001;49:281-287.
180. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996;18:669-675.
181. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999;353:983-984.
182. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427-431.
183. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002;22:1252-1258.
184. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-1217.
185. Bustos C, Hernández-Presa MA, Ortego M, et al. HMG-CoA reductase inhibiton by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998;32:2057-2064.
186. Pate GE, Tahir MN, Murphy RT, Foley JB. Anti-inflammatory effects of statins in patients with aortic Stenosis. J Cardiovasc Pharmacol Ther 2003;8:201-206.
187. Chang SM, Yazbek N, Lakkis NM. Percutaneous coronary interventions and statins therapy: Statins and prevention of periprocedural myocardial infarction. 21 May 2004 DOI: 1002/ccd.20078 http://www.medscape.com/viewarticle/572721_2.
188. Marschang P, Friedrich GJ, Ditlbacher H, et al. Reduction of soluble P-selectin by statins is inversely correlated with the progression of coronary artery disease. Int J Cardiol 2006;106:183-190.
189. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-1678.
190. Ikeda U, Shimpo M, Ohki R, et al. Fluvastatin inhibitis matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 2000;36:325-329.
191. Massaro M, Zampolli A, Scoditti E, et al. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: Anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc Res 2010;86:311-320.
192. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23:769-775.
193. Kaneider NC, Mosheimer B, Günther A, Feistritzer C, Wiedermann CJ. Enhancement of fibrinogen-triggered pro-coagulant activation of monocytes in vitro by matrix metalloproteinase-9. Thromb J 2010;8:2 (pp. 1-7).
194. Zhang YB, Li W, Yao LQ, et al. Expression changes and roles of matrix metalloproteinases in a rat model of traumatic deep vein thrombosis. Chin J Traumatol 2010;13:188-192.
195. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: A target for antiangiogenic therapy. Semin Oncol 2004;31:2-11.
196. Burleigh ME, Babaev VR, Yancey PG, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 2005;39:443-452.
197. Kitamoto S, Egashira K, Kataoka C, et al. Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J Hypertens 2000;18:1795-1800.
198. Tousoulis D, Antoniades C, Koumallos N, et al. Novel therapies targeting vascular endothelium. Endothelium 2006;13:411-421.
199. Tousoulis D, Antoniades C, Stefanadis C. Statins ameliorate atherosclerosis induced by inhibition of nitric oxide synthase: Another novel vascular protective mechanism?Int J Cardiol 2008;123:91-93.
200. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135.
201. Rikitaki Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005;97:1232-1235.
202. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997;17:265-272.
203. Essig M, Nguyen G, Prié D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998;83:683-690.
204. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999;33:1294-1304.
205. Szczeklik A, Musial J, Undas A, et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999;33:1286-1293.
206. Kumai T, Matsumoto N, Koitabashi Y, et al. Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: Candidate mechanisms for anti-lipid deposition in blood vessels. Curr Med Chem Cardiovasc Hematol Agents 2005;3:195-201.
207. Davignon J, Leiter LA. Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag 2005;1:29-40.
208. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?Am J Cardiol 2006;98:18P-25P.
209. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. Effect of atorvastatin on plasma fibrinogen. Lancet 1998;351:569-570.
210. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006;24:33-50.
211. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001;286:64-70.
212. Bays HE, Stein EA, Shah AK, Maccubbin DL, Mitchel YB, Mercuri M. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Am J Cardiol 2002;90:942-946.
213. Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Taylor AJ. Effect of atorvastatin and pravastatin on serum C-reactive protein. Am Heart J 2003;145:e8 (pp. 1-4).
214. Li JJ, Chen MZ, Chen X, Fang CH. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol 2003;26:472-476.
215. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-235.
216. Riesen WF, Engler H, Risch M, Korte W, Noseda G. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 2002;23:794-799.
217. Costa A, Casamitjana R, Casals E, et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med 2003;20:743-745.
218. Sommeijer DW, MacGillavry MR, Meijers JC, Van Zanten AP, Reitsma PH, Ten Cate H. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care 2004;27:468-473.
219. Joynt KE, Gattis WA, Hasselblad V, et al. Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol 2004;93:783-785.
220. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
221. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993;1165:335-338.
222. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998;138:271-280.
223. Suzumura K, Yasuhara M, Tanaka K, Suzuki T. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem Pharmacol 1999;57:697-703.
224. Suzumura K, Yasuhara M, Tanaka K, Odawara A, Narita H, Suzuki T. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor. Chem Pharm Bull (Tokyo) 1999;47:1010-1012.
225. Chen MF, Hsu HC, Lee YT. Short-term treatment with low-dose pravastatin attenuates oxidative susceptibility of low-density lipoprotein in hypercholesterolemic patients. Cardiovasc Drugs Ther 1997;11:787-793.
226. Girona J, La Ville AE, Solà R, Plana N, Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999;83:846-851.
227. Franzoni F, Quiñones-Galvan A, Regoli F, Ferrannini E, Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003;90:317-321.
228. Corsini A, Bernini F, Quarato P, et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996;87:458-468.
229. Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997;1345:259-268.
230. Vincent L, Chen W, Hong L, et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its anti-angiogenic effect. FEBS Lett 2001;495:159-166.
231. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001;12:383-389.
232. Mazumder B, Mukhopadhyay CK, Prok A, Cathcart MK, Fox PL. Induction of ceruloplasmin synthesis by IFN-gamma in human monocytic cells. J Immunol 1997;159:1938-1944.
233. Fleming RE, Whitman IP, Gitlin JD. Induction of ceruloplasmin gene expression in rat lung during inflammation and hyperoxia. Am J Physiol 1991;260:L68-L74.
234. Fox PL, Mazumder B, Ehrenwald E, Muhkopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Radic Biol Med 2000;28:1735-1744.
235. Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor?Atherosclerosis 2006;187:238-250.
236. Ziakas A, Gavrilidis S, Souliou E, et al. Ceruloplasmin is a better predictor of the long-term prognosis compared with fibrinogen, CRP, and IL-6 in patients with severe unstable angina. Angiology 2009;60:50-59.
237. Awadallah SM, Hamad M, Jbarah I, Salem NM, Mubarak MS. Autoantibodies against oxidized LDL correlate with serum concentrations of ceruloplasmin in patients with cardiovascular disease. Clin Chim Acta 2006;365:330-336.
238. Mandinov A, Moodie KL, Mandinova A, et al. Inhibition of in-stent restenosis by oral copper chelation in porcine coronary arteries. Am J Physiol Heart Circ Physiol 2006;291:H2692-H26927.
239. Mandinov A, Mandinova A, Kyurkchiev S, et al. Copper chelation represses the vascular response to injury. Proc Natl Acad Sci USA 2003;100:6700-6705.
240. Buyukhatipoglu H, Sezen Y, Yildiz A, et al. Effects of statin use on total oxidant and antioxidant capacity and ceruloplasmin activity. Clin Invest Med 2010;33:E313-E320.
241. Ghayour-Mobarhan M, Lamb DJ, Taylor A, et al. Effect of statin therapy on serum trace element status in dyslipidaemic subjects. J Trace Elem Med Biol 2005;19:61-67.
242. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-1536.
243. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-251.
244. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997;277:461-466.
245. Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, Leon MB. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: A device-specific analysis of 7147 patients. Circulation 2001;104:642-647.
246. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatine kinase-MB elevation after coronary intervention: Identification of an early risk period: Importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probably benefit of statin therapy. Circulation 2002;106:1205-1210.
247. Ricciardi MJ, Davidson CJ, Gubernikoff G, et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J 2003;145:522-528.
248. Veselka J, Procházková S, Duchonová R, Homolová I, Tesar D, Bybee KA. Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention. Heart Vessels 2006;21:146-151.
249. Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Eur Heat J 2004;25:1822-1828.
250. Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv 2004;62:193-197.
251. Hara H, Nakamura M, Yokouchi I, et al. Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study. Ther Adv Cardiovasc Dis 2009;3:357-365.
252. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-1756.
253. Merla R, Reddy NK, Wang FW, Uretsky BF, Barbagelata A, Birnbaum Y. Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis. Am J Cardiol 2007;100:770-776.
254. Tepliakov AT, Rybal'chenko EV. The role of cytokines in restenosing coronary stents and the efficiency of its secondary prophylaxis with statins. Klin Med (Mosk) 2008;86:32-39.
255. Iwata A, Miura S, Shirai K, et al. Lower level of low-density lipoprotein cholesterol by statin prevents progression of coronary restenosis after successful stenting in acute myocardial infarction. Intern Med 2006;45:885-890.
256. Walter DH, Fichtlscherer S, Britten MB, et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 2001;38:2006-2012.
257. Ozaydin M, Dede O, Dogan A, et al. Effects of morning versus evening intake of atorvastatin on major cardiac event and restenosis rates in patients undergoing first elective percutaneous coronary intervention. Am J Cardiol 2006;97:44-47.
258. Johnson C, Waters DD, DeMicco DA, et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). Am J Cardiol 2008;102:1312-1317.
259. Kastrati A, Schömig A, Seyfarth M, et al. PIA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999;99:1005-1010.
260. Walter DH, Schachinger V, Elsner M, et al. Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the PI(A2) allele of the platelet glycoprotein IIIa gene. Eur Heart J 2001;22:287-295.
261. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-1278.
262. Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002;106:2180-2183.
263. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-678.
264. Chan DW, Chew DP, Bhatt DL, et al. Relation of inflammation and benefit of statins after percutaneous intervention on frequency of periprocedural myocardial injury. Am J Cardiol 2004;94:1363-1366.
265. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: Impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54:2157-2163.
266. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Effeicacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: Results of the ARMYDA-TECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54:558-565.
267. Bledsoe SL, Barr JC, Fitzgerald RT, et al. Pravastatin and clopidogrel combined inhibit intimal hyperplasia in a rat carotid endarterectomy model. Vasc Endovascular Surg 2006;40:49-57.
268. Axel DI, Riessen R, Runge H, Viebahn R, Karsch KR. Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures. J Cardiovasc Pharmacol 2000;35:619-629.
269. Jaschke B, Michaelis C, Milz S, et al. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res 2005;68:483-492.
270. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998;137(Suppl):S101-S109.
271. Tam HL, Shiu SW, Wong Y, Chow WS, Betteridge DJ, Tan KC. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010;209:173-177.
272. Jinnouchi Y, Yamagishi S, Takeuchi M, et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006;6:191-193.
273. Marchetti P. Advanced glycation end products (AGEs) and their receptors (RAGEs) in diabetic vascular disease. Medicographia 2009;31:257-265.
274. Viñals F, Chambard JC, Pouysségur J. p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J Biol Chem 1999;274:26776-26782.
275. Losordo DW, Isner JM, Diaz-Sandoval LJ. Endothelial recovery: The next target in restenosis prevention. Circulation 2003;107:2635-2637.
276. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious?Circulation 2004;109:701-705.
277. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional study. Lancet 2007;369:667-678.
278. Ii M, Losordo DW. Statins and endothelium. Vasc Pharmacol 2007;46:1-9.